To include your compound in the COVID-19 Resource Center, submit it here.

Orencia abatacept regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against Orencia abatacept from Bristol-Myers in combination with methotrexate to treat moderate

Read the full 228 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE